Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models
Krzysztof Domka(Medical University of Warsaw), Małgorzata Firczuk(Medical University of Warsaw), Agnieszka Dąbkowska(Medical University of Warsaw), Justyna Jakubowska(Medical University of Lodz), Beata Krzymieniewska(Instytut Hematologii i Transfuzjologi), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Zuzanna Urbańska(Medical University of Lodz), Jaromir Hunia(Medical University of Warsaw), Łukasz Sędek(Medical University of Silesia), Elżbieta Patkowska(Institute for Transfusion Medicine), Bartosz Perkowski(Medical University of Silesia), Klaudyna Fidyt(Polish Academy of Sciences), Tomasz Szczepański(Medical University of Silesia), Magdalena Winiarska(Medical University of Warsaw), Agata Pastorczak(Medical University of Lodz), Mieszko Lachota(Medical University of Warsaw), Wojciech Młynarski(Medical University of Silesia)
Cited by 1
Related Papers
<i>β</i>‐caryophyllene and <i>β</i>‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
|Cancer Medicine|2016|642
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
The KMT2A recombinome of acute leukemias in 2023
|Leukemia|2023|214
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213